对轻度认知障碍和阿尔茨海默病的实践效应进行更深入的研究
Kevin Duff1,2, Ava Dixon2, Lindsay Embree2
1Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University, Portland, OR, USA.
概括
轻度认知障碍 (MCI) 和阿尔茨海默病 (AD) 的短期实践效应受认知状态和日常功能的影响,而不是人口统计学. 了解这些变化对于准确的诊断和治疗至关重要.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 认知心理学 认知心理学
背景情况:
- 实践效应,或测试分数的短期变化,越来越被认为是诊断和管理轻度认知障碍 (MCI) 和阿尔茨海默病 (AD) 的重要因素.
- 在MCI和AD人群中影响这些实践影响的确切因素仍然不完全理解,需要进一步调查.
研究的目的:
- 调查影响MCI和AD个体短期实践影响的大小的人口,认知,功能和并发症变量.
- 澄清不同认知状态的老年人实践效应和临床变量之间的关系.
主要方法:
- 一项涉及166名老年人的观察性研究,分类为认知完整,记忆力衰竭或轻度AD.
- 参与者在一周的时间间隔内两次接受了简短的神经心理测试电池.
- 使用相关性和回归分析来评估实践效应与人口,认知和临床因素之间的关联.
主要成果:
- 实践效应与人口统计信息和医疗并发症的相关性很小.
- 在实践效应和认知性能指标之间发现了显著的关系.
- 抑郁症状和日常功能水平也被发现与实践效应的大小有显著的关联.
结论:
- 在MCI和AD的短期实践影响主要与认知变量,抑郁症状和日常功能有关,而不是人口或并发症因素.
- 这些发现增强了对神经退行性疾病中的实践影响的理解,有可能改善临床护理和研究方法.
- 对实践效应的细微认识可以帮助在MCI和AD中进行更准确的诊断和预后评估.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
165
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
165
01:26Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
01:22Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
01:30Cognitive Development During Adulthood
165
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
165
01:30Dementia
143
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
143